- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07603375
Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma (TNT Esophagus)
A Single-arm Study of Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma
The goal of this trial is to learn if adding consolidative chemotherapy to routine chemoradiation can better control both local recurrence and metastasis and reduce the need for surgical intervention.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Clinical Trials Office
- Telefoonnummer: (919) 668-3726
- E-mail: RadOnc-Clinical_Trials@dm.duke.edu
Studie Locaties
-
-
North Carolina
-
Durham, North Carolina, Verenigde Staten, 27710
- Werving
- Duke University Medical Center
-
Hoofdonderzoeker:
- Manisha Palta, MD
-
Contact:
- Kaitlin Bailey, RN BSN OCN
- Telefoonnummer: (919) 668-3726
- E-mail: RadOnc-Clinical_Trials@dm.duke.edu
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Subject must be able to provide study specific informed consent prior to study entry
- Must be newly diagnosed, histologically proven diagnosis of adenocarcinoma of the thoracic esophagus or gastroesophageal junction (Siewert I-II);
- Stage II-IVA, excluding T4b, according to the American Joint Committee on Cancer (AJCC) 8th edition;
- Complete history and physical examination within 21 days of signing consent;
- Staging whole-body FDG-PET/CT (fluorodeoxyglucose-positron emission tomography/computed tomography) scan with or without contrast (preferred) or chest/abdominal (CT with contrast) confirming there is no evidence of metastatic disease must be obtained within 45 days of study enrollment
- ECOG (Eastern Cooperative Oncology Group) performance status of 0-2
- Subjects must be appropriate candidates for planned chemoradiation (concurrent carboplatin/paclitaxel) and chemotherapy (FLOT, m-FOLFOX-6) as determined by the treating radiation oncologist, medical oncologist, and surgical oncologist.
- Adequate hematologic, renal, and hepatic function within 14 days of initiation of therapy
Exclusion Criteria:
-
Cervical esophageal cancers arising 15-18 cm from the incisors.
-
Esophageal squamous cell carcinoma.
-
Patients with T4b disease according to the AJCC 8th Edition.
-
Definitive clinical or radiologic evidence of metastatic disease.
-
Has had prior systemic therapy or radiation therapy for the current diagnosis.
-
Prior thoracic radiotherapy for any reason that would result in overlap of radiation therapy fields; all patients with prior radiotherapy must be reviewed by the PI to determine if patient is eligible.
-
Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer
-
Severe, active co-morbidity defined as follows:
- Active uncontrolled infection requiring IV antibiotics;
- Pregnant and/or nursing subjects;
- HIV positive with CD4 count < 200 cells/microliter. Note that subjects who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count ≥ 200 cells/microliter within 30 days prior to registration. Note also that HIV testing is not required for eligibility for this protocol. This exclusion criterion is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
-
Has a history or current evidence of physical or physiological contraindication to participation in this study, at the discretion of the treating investigator.
-
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Chemoradiation with consolidative chemotherapy
Participants will receive a standard course of chemoradiation followed by consolidative chemotherapy (FOLFOX regimen at the treating physician's discretion). |
Modified-FOLFOX-6 or FLOT (Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel) |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of participants with Clinical complete response (cCR)
Tijdsspanne: approximately 36 weeks
|
cCR defined as absence of malignancy on endoscopic biopsies obtained at the time of reassessment following neoadjuvant therapy |
approximately 36 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of participants who complete both chemoradiation and chemotherapy
Tijdsspanne: approximately 36 weeks
|
approximately 36 weeks
|
|
|
Number of participants with pathologic complete response (pCR)
Tijdsspanne: approximately 36 weeks
|
Pathologic complete response (pCR) is defined as absence of detectable tumor of esophagectomy tissues. |
approximately 36 weeks
|
|
Number of participants with local control
Tijdsspanne: up to 5 years
|
Local control in participants achieving clinical complete remission (cCR) estimated using the Kaplan-Meier method. cCR is defined as the disappearance of all detectable signs and symptoms of a disease, such as cancer, have completely disappeared. |
up to 5 years
|
|
Number of participants with Disease free survival
Tijdsspanne: up to 5 years
|
Disease free survival in participants achieving cCR estimated using the Kaplan-Meier method. cCR is defined as the disappearance of all detectable signs and symptoms of a disease, such as cancer, have completely disappeared. |
up to 5 years
|
|
Time to distant metastasis
Tijdsspanne: up to 5 years
|
Time to distant metastasis in participants achieving cCR estimated using the Kaplan-Meier method. cCR is defined as the disappearance of all detectable signs and symptoms of a disease, such as cancer, have completely disappeared. |
up to 5 years
|
|
Overall survival
Tijdsspanne: up to 5 years
|
Measured in participants achieving cCR and estimated using the Kaplan-Meier method. cCR is defined as the disappearance of all detectable signs and symptoms of a disease, such as cancer, have completely disappeared. |
up to 5 years
|
|
Number of participants with Local control
Tijdsspanne: up to 5 years
|
Measured in participants achieving pCR and estimated using the Kaplan-Meier method. pCR is defined as absence of detectable tumor of esophagectomy tissues. |
up to 5 years
|
|
Disease free survival
Tijdsspanne: up to 5 years
|
Disease free survival in participants achieving pCR. pCR is defined as absence of detectable tumor of esophagectomy tissues. |
up to 5 years
|
|
Time to distant metastasis
Tijdsspanne: up to 5 years
|
Time to distant metastasis in participants achieving pCR estimated using the Kaplan-Meier method. pCR is defined as absence of detectable tumor of esophagectomy tissues. |
up to 5 years
|
|
Overall survival
Tijdsspanne: up to 5 years
|
Measured in participants achieving pCR and estimated using the Kaplan-Meier method. pCR is defined as absence of detectable tumor of esophagectomy tissues. |
up to 5 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Manisha Palta, MD, Duke Health
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Hoofd- en nekneoplasmata
- Slokdarmaandoeningen
- Slokdarmneoplasmata
- Adenocarcinoom van de slokdarm
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Enzymen en co -enzymen
- Coördinatiecomplexen
- Pyrimidines
- Formyltetrahydrofolates
- Tetrahydrofolaten
- Foliumzuur
- Pterins
- Pteridines
- Uracil
- Pyrimidinonen
- Co -enzymen
- Oxaliplatine
- Fluorouracil
- Leucovorin
- FOLFOX -protocol
Andere studie-ID-nummers
- Pro00120182
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Data may be shared 6 months after publication or as required by the journal
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .